Related references
Note: Only part of the references are listed.Amelioration of anti-Thy1-glomerulonephritis by PPAR-γ agonism without increase of endothelial progenitor cell homing
Peter E. Westerweel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction
Masatoshi Kuratsune et al.
NEPHROLOGY (2007)
Differentiation of human circulating fibrocytes as mediated by transforming growth factor-β and peroxisome proliferator-activated receptor γ
Kurt M. Hong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Protective effects of peroxisome proliferator-activated receptor γ ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury
Shigehiro Doi et al.
TRANSPLANTATION (2007)
Troglitazone and pioglitazone interactions via PPAR-γ-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines
Francesco Turturro et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy
J-A Moon et al.
KIDNEY INTERNATIONAL (2006)
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
George L. Bakris et al.
JOURNAL OF HYPERTENSION (2006)
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist:: Molecular mechanism of the antiproteinuric effect of pioglitazone
Ariela Benigni et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation
T Hirai et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Pathogenesis of renal injury in obstructive uropathy
Robert L. Chevalier
CURRENT OPINION IN PEDIATRICS (2006)
Obstructive nephropathy: towards biomarker discovery and gene therapy
RL Chevalier
NATURE CLINICAL PRACTICE NEPHROLOGY (2006)
Renal fibrosis: New insights into the pathogenesis and therapeutics
YH Liu
KIDNEY INTERNATIONAL (2006)
Troglitazone's rapid and sustained activation of ERK1/2 induces cellular acidosis in LLC-PK1-F+ cells:: physiological responses
R Oliver et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Agonist of peroxisome proliferator-activated receptor-γ, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model
S Lee et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production:: implications for therapy of lung fibrosis
HA Burgess et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK
I Kiribayashi et al.
KIDNEY INTERNATIONAL (2005)
Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK:: a mechanism for activation of latent TGF-β1
T Naito et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2004)
The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells
U Panchapakesan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2004)
Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention
YH Liu
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
E Chiquette et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses
S Zafiriou et al.
KIDNEY INTERNATIONAL (2004)
Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury
A Sivarajah et al.
AMERICAN JOURNAL OF NEPHROLOGY (2003)
PPARγ ligand attenuates PDGF-induced mesangial cell proliferation:: Role of MAP kinase
SS Ghosh et al.
KIDNEY INTERNATIONAL (2003)
c-Fos-driven transcriptional activation of transforming growth factor β1:: inhibition of high glucose-induced promoter activity by thiazolidinediones
C Weigert et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney
T Masaki et al.
KIDNEY INTERNATIONAL (2003)
Obstructive nephropathy and renal fibrosis
S Klahr et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2002)
Effects of different PPARγ-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis
U Panzer et al.
KIDNEY INTERNATIONAL (2002)
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro
A Galli et al.
GASTROENTEROLOGY (2002)
Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro
RE Routh et al.
KIDNEY INTERNATIONAL (2002)
The role of PPARs in the transcriptional control of cellular processes
YF Guan et al.
DRUG NEWS & PERSPECTIVES (2002)
15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells
K Takeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
YF Guan et al.
KIDNEY INTERNATIONAL (2001)
Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats
LJ Ma et al.
KIDNEY INTERNATIONAL (2001)
Antibody to transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction
A Miyajima et al.
KIDNEY INTERNATIONAL (2000)
Renal protective effect of troglitazone in Wistar fatty rats
K Fujiwara et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
K Isshiki et al.
DIABETES (2000)
Share Paper
